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Despite the high prevalence of epilepsy in sub-Saharan Africa and the established relationship between depression and epilepsy, the extent of comorbid epilepsy and depression in
the region is still poorly understood. The objective of this systematic review and meta-analysis is to address this gap in the literature by determining the pooled prevalence of depression among epileptic patients in sub-Saharan Africa.

Methods
A systematic desk review and electronic web-based search of PubMed, Google Scholar,
EMBASE, PsycINFO and the World Health Organization’s Hinari portal (which includes the
SCOPUS, African Index Medicus, and African Journals Online databases) conducted from
December 2, 2017 to February 30, 2018, identified peer-reviewed, original research articles
and doctoral dissertations using pre-defined quality and inclusion criteria. Relevant data
were extracted and descriptive summaries of the studies presented in tabular form. The I2
statistic was used to assess heterogeneity across studies. Funnel plot asymmetry and
Egger’s tests were used to check for publication bias and the methodological quality of the
included studies were assessed using the scale developed by Hoy and colleagues. The
pooled prevalence of comorbidity at a 95% confidence interval (CI) was determined by
applying a trim and fill analysis in a random-effects model.

Results
Our search identified 167 studies, of which 14 original research articles and two doctoral dissertations reporting on case-control and cross-sectional studies were eligible for inclusion in
the final analysis. The pooled estimate of prevalence of depression among patients with epilepsy was 32.71% (95% CI: 25.50–39.91%). Regional sub-group analysis found that the
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pooled prevalence in East Africa was 34.52% (95% CI: 23.53–45.51%) and 29.69% (95%
CI: 22.7–36.68%) in Southern and West Africa. The odds of depression among epileptic
patients receiving polytherapy were 2.65 higher than in those receiving monotherapy (95%
CI: 1.49–4.71, I2 = 79.1%, p < 0.05).

Conclusion
Our findings indicate high comorbidity in sub-Saharan Africa and suggest that it may be
more prevalent there than elsewhere. Comorbidity is statistically associated with polytherapy in the studies reviewed. Given the high levels of comorbidity in the region, more attention should be paid to incorporating depression screening and treatment into existing
epilepsy programs and to revising treatment guidelines on comorbid depression to reduce
polytherapy.

Introduction
Epilepsy is one of the most common neurological disorders globally, and in sub-Saharan
Africa, where it affects approximately 10 million people annually [1]. Untreated, epilepsy can
cause traumatic injuries, impair physical functioning, and reduce social engagement. This in
turn can result in significant psychological stress and premature death.
People with epilepsy (PWE) are more vulnerable to psychiatric illnesses: rates of psychiatric illness are 9% higher among PWE than in the general population and rates of depression,
22% higher [2]. Depression is the most common psychiatric disorder in PWE [3], and major
depressive episodes, one of the most common diagnoses. Social stigma, feelings of frustration
and low self-esteem due to the danger and unpredictability of epilepsy, and the psychotropic
effects of antiepileptic drugs (AEDs) have all been posited as reasons for the strong association between the two illnesses [4]. Scholars such as Andres Kanner have also argued that the
association between depression and epilepsy may be bi-directional, with people who are
depressed having higher risk for developing epilepsy perhaps due to “structural, neuropathological, and neurotransmitter disturbances associated with primary major depressive disorders” [5].
Having a depression-related comorbidity is associated with poorer quality of life and
increased suicidal ideation for epileptic patients [2,6]. Greater severity of comorbid depression
with epilepsy is associated with significantly reduced overall seizure recovery, higher seizure
severity, and increased cognitive, emotional, and physical illness [7,8]. Clinicians may also find
managing anti-depression treatment particularly challenging for their patients with epilepsy
due to concerns about drug interactions, the side effects of polytherapy, and fears of lowering
seizure thresholds [9,10].
In addition to complicating treatment and reducing quality of life, depression in PWE also
strains health systems, particularly in low-income countries, because PWE with untreated
depression tend to use significantly more health resources. For example, Cramer et al.’s studies
of health care utilization among comorbid patients found that epileptic patients with mild to
moderate depression had a two-fold increase in medical visits, and those with severe depression, a four-fold increase, compared to those who were not depressed [7,11]. Moreover, studies
suggest that depressed patients might be less adherent to epilepsy treatment than their nondepressed counterparts [12] and may respond relatively poorly to drug treatment [13].
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Several factors have been found to be associated with increased risk of depression in the epileptic population. In sub-Saharan Africa, lower educational status, lower monthly income, frequency of seizure, the side effects of AEDs, and difficulties adhering to AEDs have all been
found to be prominent risk factors for depression [14–18]. Polytherapy has also been reported
as an important factor, but the association between depression and polypharmacy exhibits significant variation across studies; some finding a significant positive association [14–16,19] and
others none [17].

Prevalence of depression and epilepsy in sub-Saharan Africa
Studying the psychiatric comorbidities of epilepsy in sub-Saharan Africa is important because
of the high prevalence of epilepsy in the region. This elevated prevalence is thought to be due
to the endemicity of bacterial and parasitic infections that affect the central nervous system
and to poor labor and delivery and perinatal care practices that result in head trauma in infants
and young children [20,21] For example, febrile convulsions in children brought on by
malaria, bronchopneumonia, and upper respiratory tract infections are reported extremely frequently in sub-Saharan African health systems as a significant cause of seizures [1] and it is
unclear how often of these febrile convulsions continue as partial epilepsy. In addition, infections such as meningitis, encephalitis, and septicemia might affect the brain directly, leading to
epilepsy[1]
Sub-Saharan Africa also has a significant burden of depression. Globally, depressive disorders are the single largest contributor to non-fatal poor health (7.5% of all years lived with
disability) and more than 80% of this burden is concentrated in low- and middle-income
countries, with Sub-Saharan Africa’s 29 million cases accounting for 9% of the global burden
[22]. WHO estimates that 6% of women and 5% of men in sub-Saharan Africa have depression; and with growing populations, urbanization, and aging, it is expected that this prevalence
will increase markedly in the coming decades[22]. Despite the significant prevalence of depression in sub-Saharan Africa it, and other behavioral illnesses are rarely prioritized in public
health policies[23,24].
It is reasonable to expect that the prevalence of depression and epilepsy comorbidity and its
negative health and socio-economic effects would be more pronounced in the sub-Saharan
African region where social stigma surrounding epilepsy is pronounced, and the availability of
adequate treatment lacking. People with epilepsy in sub-Saharan Africa may experience severe
isolation and discrimination in many areas of life, including the health care sector because epilepsy is often perceived as a curse, a mental illness, or a contagious disease[1].
Studying the extent of depression and epilepsy comorbidity in sub-Saharan Africa is complicated by the fact that only about 20% of PWE in low- and middle-income countries receive
treatment [1] and by poor estimates of the underlying population prevalence of both diseases.
It is difficult to gauge the reliability of epidemiological figures on these diseases because of the
lack of consistent standards for data collection on them and, in particular, a tendency to conflate epilepsies with generalized convulsive seizures [1].
While there is relatively consistent evidence of high prevalence of comorbidity globally,
most systematic reviews to date have included either no African studies [25,26] or only one or
two studies from the continent [27] while the African literature on the subject has been characterized by considerable variability, inconsistency, and inconclusive findings.
Better information on the extent of this comorbidity and its association with polytherapy is
important for reducing inappropriate treatment of PWE and for improving suicide prevention
efforts in this vulnerable population [28]. Documenting the extent of comorbidity may also
help to highlight the need for more active mental health policy making in the region. This
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systematic review and meta-analysis therefore, aims to synthesize evidence on the prevalence
of depression among epileptic adults, children, and adolescents and its association with drug
therapy in sub-Saharan Africa.

Methods
Search approach and appraisal of studies
Original research articles and doctoral dissertations reviewed in this meta-analysis were
accessed through electronic web-based database searches, desk reviews of doctoral dissertations, and reference list reviews using the Preferred Reporting Items of Systematic Reviews
and Meta-Analysis (PRISMA) checklist guidelines [29].
The electronic databases searched were PubMed, Google Scholar, Embase, PsycINFO and a
World Health Organization (WHO) database portal for low- and middle-income countries
that includes the Web of Science, SCOPUS, African Index Medicus (AIM), Cumulative Index
to Nursing and Allied Health Literature (CINAHL), WHO’s Institutional Repository for Information Sharing (IRIS) and African Journals Online databases. In addition, the researchers
found related articles through a desk review of the doctoral dissertations available at Ethiopian
university libraries and institutional repositories, and from reviewing the reference lists of
related articles.
Searches were conducted from December 1, 2017 to January 30, 2018. The researchers
used, among others, the following key terms for the database searches: “depression” AND “epilepsy” OR “co-morbid depression” AND “epilepsy” OR “mental illness” AND drug therapy
“OR “treatment” AND “sub-Saharan Africa”. Please see the S1 Table for a list of exact search
terms used for each database and the number of results found in each search.

Inclusion and exclusion criteria
All English-language, full-text, original research articles and doctoral dissertations on observational studies (case-control or cross-sectional) conducted in the sub-Saharan Africa region
from 2005 to 2017, with adults, children or adolescents, that were published in peer-reviewed
journals or filed as completed dissertations, that used internationally accepted scales to measure epilepsy and depression (e.g., Beck’s Depression Inventory scale or the Hospital Anxiety
and Depression Scale), that defined epilepsy and depression according to internationally
accepted definitions (e.g., DSM-IV), and that concerned comorbid depression and epilepsy
were eligible for inclusion.

Data extraction and quality assessment
After initial screening, two reviewers (FW and GD) downloaded abstracts to assess them for
inclusion. If reviewers disagreed about whether a search result was relevant to the study, it was
included for retrieval. The relevance of the items was then evaluated based on the item’s title,
topic, objectives, and methodology as listed in the abstract. Abstracts were also assessed for
agreement with the inclusion criteria. At this stage, articles deemed irrelevant or out of the
scope of the study were excluded and the full text of the remainder downloaded for a detailed
review. When it was unclear whether an abstract was relevant, or there was disagreement
among reviewers on whether it met the inclusion criteria, it was included for retrieval. Two
reviewers (GD and FW) then assessed the quality of potentially eligible articles using the Newcastle-Ottawa Scale (NOS) criteria [30]. The average of two independent reviewers’ score was
used to determine whether the articles should be included. Discrepancies in quality assessment
scores were resolved with a third reviewer (HM), whenever appropriate. Articles whose NOS
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quality scores were less than six; those that had methodological flaws, or incomplete reporting
of results; or those for which full text was not available were excluded from the final analysis.
Study researchers made two separate attempts to contact article authors whenever additional
study information was needed; for example, when patient outcome data were incomplete.

Outcome of interest
The outcome of interest was the pooled prevalence of depression among epileptic patients in
sub-Saharan Africa. Prevalence was measured as the number of comorbid study subjects
divided by the number of patients in a study multiplied by 100. We also estimated the association (as measured by crude odds ratios) between comorbidity and polytherapy as a secondary
outcome.

Data analysis
Information on the study characteristics (time frame, study location, study design, sample size,
number of comorbid patients, and the age-range of patients) was extracted from each study
using a Microsoft Excel spreadsheet template. These data were then transferred to Stata version
11 software, which was used to calculate the pooled prevalence of depression among epileptic
patients, perform tests, and to identify the significant association between the outcome variable
and factors. The heterogeneity of study outcomes was assessed using the I2 statistic [31]. We
used funnel plot asymmetry and Egger’s and Begg-Mazumdar Rank correlation tests to check
for publication bias [32]. Because the results of these tests suggested the possible existence of
significant publication bias, a random effects model was used to estimate the pooled prevalence of comorbidity at a 95% confidence interval (CI) [33]. In addition, we conducted a geographic subgroup analysis. To confirm results, two researchers independently carried out the
main statistical analysis and results were cross-checked for consistency.

Assessment of methodological quality of included studies and risk of bias
We evaluated the risk of bias in the studies that were selected using the 10-item rating scale
developed Hoy et al. for prevalence studies (see S2 Table) [34]. The tool assesses studies on 10
domains, including sampling, data collection, reliability and validity of study tools, case definition, and prevalence periods. Researchers categorized each study as having low risk of bias
(“yes” answers to domain questions) or high risk of bias ("no" answers to domain questions).
Each study was assigned a score of 1 (Yes) or 0 (No) for each domain, and these scores were
summed to provide an overall study quality score. Scores of 8–10 were considered as having a
“low risk of bias”, 6–7 a “moderate risk”, and 0–5 a “high risk”. For the final risk of bias classification, disagreements between the reviewers were resolved via consensus.

Results
Identification and description of studies
The database search and desk review yielded a total of 167 articles (Fig 1). Of these, 133 articles
were found in PubMed, EMBASE, PsycINFO, Hinari and Google Scholar and the remaining
34 were found from the desk review. After reviewing the titles and abstracts, we excluded 143
items due to duplication. The abstracts of the remaining 24 items were downloaded and
assessed for eligibility. One article from Ethiopia was excluded because the full text was not
available [35]. Two articles from Zambia were excluded due to irrelevance [36,37]. In step
three, the full text of the remaining 21 articles was assessed for quality and appropriateness.
Three articles from Nigeria [38], Togo [39] and Benin [39] were excluded due to low quality
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Fig 1. Flow diagram for selection of studies.
https://doi.org/10.1371/journal.pone.0202613.g001

scores. Two articles from Sierra Leone [40] and Zambia [41] were excluded because the study
outcome was not clearly stated.
The remaining 16 studies were included in the analysis (Fig 1). The 16 articles reported on
six cross-sectional studies from Ethiopia [15–18,42,43], one cross-sectional study from Kenya
[14], four cross-sectional studies and one case–control study from Nigeria [44–48], two crosssectional studies from Rwanda [49,50], one case–control study from Sudan [51] and one
cross-sectional study from Zambia [52].

Characteristics of included studies
Sixteen studies with a total sample of 4,314 epileptic patients whose ages ranged from 9 to 65
were assessed (Table 1). The majority of studies were conducted in Ethiopia [15–18,42,43],
and Nigeria [44–48]. The remaining were from Rwanda [49,50], Sudan [51], Zambia [52] and
Kenya [14]. Studies were mostly found in small, regional, peer-reviewed journals, and two
were reported in doctoral dissertations.
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Table 1. Characteristics of included studies for systematic review and meta-analysis, 2005–2017, sub-Saharan Africa.
Study

Source Type Study
year

Country Study
(Region) design

Age of
subjects

Sample
size

Response
rate

Depression
measure

Depression
Quality
prevalence (%) Score

Factors positively
associated with
depression

Tsegabrhan,
et al [17]

Journal

2014

Ethiopia
(East)

Crosssectional

�18
years

300

100%

BDI

49.3

7

Lower educational
status
Higher seizure
frequency
Higher perceived
stigma

Tegegne et al
[16]

Journal

2015

Ethiopia
(East)

Crosssectional

�18
years

415

98%

HADS

32.8

8

Lower educational
status
Polytherapy
Higher perceived
stigma

Bifftu et al
[15]

Journal

2015

Ethiopia
(East)

Crosssectional

�18
years

405

96%

BDI

45.2

7

Lower educational
status
Higher seizure
frequency
Polytherapy
Higher perceived
stigma
Early onset of
seizures
Difficulty adhering to
AEDs

Tegegne et al
[43]

Journal

2014

Ethiopia
(East)

Crosssectional

�18
years

415

98%

HADS

32.8

8

(not assessed)

Bifftu et al
[42]

Journal

2015

Ethiopia
(East)

Crosssectional

�24
years

408

97%

BDI-II

45.1

8

(not assessed)

Tilahune et al
[18]

Journal

2016

Ethiopia
(East)

Crosssectional

�18
years

326

100%

PHQ

24.5

7

Female gender
Greater age
Divorced
Lower income

Kiko [14]

Dissertation 2013

Kenya
(East)

Crosssectional

�18
years

327

Not stated

BDI

16.5

7

Polytherapy
(associated with mild
depression)

Adewuya et al
[44]

Journal

2005

Nigeria
(West)

Crosssectional

12–18
years

102

90%

DISC-IV

28.4

8

Polytherapy
Higher perceived
stigma
Uncontrolled
seizures

Ayanda et al
[45]

Journal

2016

Nigeria
(West)

Crosssectional

18–68
years

74

Not stated

MINI

21.6

8

Not assessed

Owolabi et al
[48]

Journal

2016

Nigeria
(West)

Crosssectional

�18
years

255

Not stated

MINI

20.4

8

Higher seizure
frequency
Early onset of
seizures (duration of
epilepsy)
Previous
hospitalization for
epilepsy

Mosaku et al
[46]

Journal

2006

Nigeria
(West)

Crosssectional

1838years

51

Not stated

HADS

27.5

7

Not assessed

Ogunrin et al
[47]

Journal

2010

Nigeria
(West)

Case–
control

1865years

152

Not stated

BDI, HRSD

42

8

Female gender
Uncontrolled
seizures
Duration of epilepsy
Difficulty adhering to
AEDs
(Associated with both
BDI & HRSD)
(Continued )
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Table 1. (Continued)
Study

Source Type Study
year

Country Study
(Region) design

Age of
subjects

Sample
size

Response
rate

Depression
measure

Depression
Quality
prevalence (%) Score

Factors positively
associated with
depression

Sezibera et al
[50]

Journal

2013

Rwanda
(East)

Crosssectional

9–68
years

105

Not stated

HRSD

48.6

8

Female gender
Greater age
Lower educational
status

Mutabazi [49]

Dissertation 2014

Rwanda
(East)

Crosssectional

18–73
years

382

Not stated

MINI

6.5

8

Not assessed

Saadalla et al
[51]

Journal

2016

Sudan
(East)

Case–
control

18–70
years

200

Not stated

BDI

45.5

7

Not assessed

Veneviv et al
[52]

Journal

2016

Zambia
(South)

Crosssectional

�18
years

397

Not stated

BPRS

39.4

7

Not assessed

Beck’s Depression Inventory (BDI); Brief Psychiatric Rating Scale (BPRS); Diagnostic Interview Schedule for Children Version IV (DISC-IV); Hospital Anxiety and
Depression Scale (HADS); Hamilton Rating Scale for Depression (HRSD); Mini International Neuropsychiatric Interview (MINI); Patient Health Questionnaire.
https://doi.org/10.1371/journal.pone.0202613.t001

Most studies were cross-sectional, but two [47,51] used a case-control design. All studies
recruited participants from in-patient or out-patient clinical settings. Five of the studies stated
the age of onset of epilepsy and its duration. In these studies, the age of epilepsy onset ranged
from 9 to 30 years of age [15,16,42,43,48] and the duration of disease ranged from 1 to 15 years
[15,16,42,43,52]. Half of the studies examined the factors associated with depression in PWE;
four studies examined the factors related to PWE having depressive disorder [15,16,43,47].

Quality assessment and risk of bias
Most studies had moderate sample sizes; only two had small samples of less than 100 participants [45,46]. Reported response rates were high (>90%) but more than half of the studies did
not report a response rate and only one discussed the characteristics of non-responders. All
studies used standardized methods for measuring depression with the Beck’s Depression
Inventory (BDI) and the Hospital Anxiety and Depression Scale (HADS) being the tools most
frequently used.
Due to our initial quality screening, all of the studies included in the final review had either
medium or high quality using the Hoy et al. risk of bias [34] tool. Twelve of the 16 studies
(75%) received a high quality score (�8 points) and the remaining 4 studies (25%) were scored
as being of medium quality (5–7 points) (see S2 Table).

Publication bias
Both funnel plots of precision asymmetry and the Egger’s test of the intercept indicated the
presence of publication bias. Visual examination of the funnel plot showed it to be asymmetric
(Fig 2) and Egger’s test of the intercept (B0) was 0.54 (95% CI: 0.20–0.87 p<0.05). To mitigate
against publication bias we applied a trim and fill analysis in the random effects model. The
prevalence estimates did not differ significantly between the initial model and the trim and fill
model.

Prevalence of depression in PWE
Depression prevalence ranged from a high of 49.3% in an Ethiopian study [17] to a low of
6.5%, reported in a study conducted in Rwanda [49].
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Fig 2. Funnel plot for systematic review of the prevalence of depression among epileptic patients, 2005–2017 in subSaharan Africa.
https://doi.org/10.1371/journal.pone.0202613.g002

Because the I2 statistic for heterogeneity indicated significant difference between the studies
(I = 98%, p<0.05) and because theoretically we expected that the settings and socio-economic
contexts might differ radically across these studies, we fitted a DerSimonian and Laird random
effects model to estimate the pooled prevalence of depression [53,54]. In the model, each individual study is given a weight based on its reported effect size and sample size [55]. The studies
with the largest weight were Michel [49], Kiko [14], and Tegegne et al [16] with respective
weights of 6.5%, 6.4%, and 6.4%. Smaller weights were given for Mosaku, 5.7%, [46], Sezibera
et al 6.0%, [50] and Ayanda et al 6.0% [45] (Fig 3).
The average pooled estimate of depression among epilepsy patients was 32.71% (95% CI:
25.50–39.91%) (Fig 3). Sub-group analysis by geographic region found that the pooled prevalence of depression among epileptic patients in East Africa was 34.52% (95% CI: 23.53–
45.51%) and among patients in Southern and West Africa, 29.69% (95% CI: 22.7–36.68%)
(Fig 3).
2

Factors associated with depression among PWE
The factors most frequently associated with depression in PWE were, in order, lower educational status [15–17,50], higher perceived stigma [15–17,44], polytherapy [14,16,17,44], female
gender [18,47,50], the frequency of seizures [15,17,48], having controlled seizures [44,47], the
duration of epilepsy [15,47] and greater age [18,50].
Four of the studies explicitly intended to find factors associated with depression in epilepsy
patients [15–17,44]. One of the factors most strongly associated with depression among PWE
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Fig 3. Forest plot of 16 studies assessing prevalence of depression among epilepsy patients, 2005–2017, sub-Saharan Africa.
https://doi.org/10.1371/journal.pone.0202613.g003

in these studies was polytherapy (i.e., the amount of different medications patients received).
The pooled odds of depression among epilepsy patients receiving polytherapy was 2.65 (95%
CI: 1.49–4.71) when compared with patients receiving monotherapy (Fig 4).

Discussion
Key findings
This systemic review and meta-analysis attempted to estimate the pooled prevalence of depression and its association with polytherapy among PWE in sub-Saharan Africa. We found a very
high prevalence of depression (32.71%) among PWE. This estimate was roughly 10 percentage
points larger than that reported in recent meta-analyses, which reviewed studies that were
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Fig 4. Forest plot of four studies examining the association of polytherapy with depression among epilepsy patients, 2005–2017, sub-Saharan Africa.
https://doi.org/10.1371/journal.pone.0202613.g004

almost exclusively conducted in Europe, the Americas, or Asia [25–27]. In the one recent
cross-national meta-analysis that included two studies from sub-Saharan Africa, the region
was found to have the highest regional prevalence of comorbidity, although that pooled prevalence, 25.6%, was lower than that found in our study [27].
Although we expected to find significant comorbidity due to the well-established bi-directional relationship between the depression and epilepsy [3,56], the high prevalence of depression reported in the studies under review suggest that the psychological toll of the epilepsy
may be particularly severe in sub-Saharan African settings where the illness is poorly managed,
treatment options limited, epilepsy-related stigma high, and the social and economic costs of
illness particularly acute. The relationship between depression and epilepsy is not only neurological but also triggered and shaped by socioeconomic factors [57]. In settings where epilepsy
is thought to be a potentially contagious spiritual curse, PWE face profound social isolation
and limited prospects for education, employment, and marriage [21] leaving them physically,
emotionally, and economically vulnerable. In addition, endemic poverty in many communities
means that PWE must manage the stress of affording treatment while maintaining their livelihoods in households that are often food insecure and financially precarious. The argument
that high social stigma, poor treatment, and low socio-economic status in sub-Saharan Africa
are important drivers of the region’s higher rates of comorbidity is supported by the findings
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in the individual studies reviewed that these factors are significantly associated with depression
among PWE.
A secondary objective of this study was to determine the effect of polytherapy on the prevalence of depression in PWE. We found that polytherapy doubled the odds of depression
(OR = 2.65; 95% CI: 1.49–4.71) compared with monotherapy. Polytherapy not only increases
pill burden, making adherence, and therefore control of seizures, more difficult, it also
increases the risk of adverse drug reactions and the severity of those reactions [58,59]. In addition, patients taking multiple medications have higher risk of drug-to-drug interactions and
may be more prone to medication errors [58,59]. Our findings suggest that greater emphasis
should be placed on assessing pill burden, tolerability, and potential drug interactions as well
as on providing appropriate health education about drug regimens when designing epilepsy
treatment guidelines and health care provider training curricula.
Our regional sub-group analysis found higher prevalence of depression in East Africa than
in Southern and West Africa (34.52% vs. 29.69%). This difference may be due to the large
number of East African studies that were conducted in Ethiopia, which has a particularly weak
mental health care system compared to other regions. Poorly controlled epilepsy is a risk factor
for depression and Ethiopia lacks the person power and infrastructure to manage epilepsy well
for the majority of patients in need. For example, for a country of almost 100 million people,
Ethiopia has only approximately 63 psychiatrists, 150 Masters-level mental health professionals, and 200 Bachelors-level psychiatry nurses [60] and most of these providers are concentrated in the capital city. Non-mental health professionals are often assigned to provide mental
health services in Ethiopia, but studies indicate that they lack the knowledge required to deliver
comprehensive mental health care [61]. Ethiopia’s mental health system also faces many other
challenges that complicate treatment of epilepsy such as delayed and inadequate supportive
supervisions for trainees, lack of funding for supportive supervision and mentoring, and interrupted drug supplies [60]. Ethiopia’s overall level poverty compared to Zambia and Nigeria
may also contribute to the difference in regional prevalence rates, since as discussed above,
poor socio-economic status is associated with depression in PWE.

Study limitations
There are several limitations in this review. First, we were only able to review English-language
studies because we lacked investigators who were fluent in the other languages of interest
(French and Portuguese), and we were reluctant to introduce translation biases by using translation services to search for, and to translate articles. This may have caused us to omit important studies from Francophone and Lusophone Africa and, therefore, may have reduced the
credibility of this review. However, it has been found that language bias in meta-analyses
reporting pooled estimates, as this study does, may be less severe than in other types of reviews
[62,63]. Our second limitation is that many of the studies reviewed were published in small
regional journals or were doctoral dissertations making it difficult to gauge the extent of peer
review. Moreover, due to the absence of data, crude odds ratios were used to estimate factors
related with comorbidity, which prevented us excluding confounding factors. Finally, our systematic review and meta-analysis protocol was not registered online. The findings of this
meta-analysis would be best interpreted keeping these analytical limitations and the limitations
of the original studies in mind.

Conclusion
This meta-analysis found that the prevalence of comorbid depression with epilepsy in subSaharan Africa was high, and may be of greater magnitude than that reported in other
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geographic regions. We also find that in these studies, comorbidity is significantly associated
with polytherapy. These findings together with the high overall prevalence of epilepsy in subSaharan Africa, suggest that more attention should be paid to increasing health education on
epilepsy in order to reduce stigma. Incorporating depression screening and treatment into
existing epilepsy programs and revising treatment guidelines on comorbid depression to
reduce polytherapy may also be warranted. Future research on this subject in sub-Saharan
Africa should focus on identifying appropriate medication regimens for patients with comorbid depression.
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